Pharmaco-epidemiology: What do (and don't) we know about utilisation and impact of psychotropic medications in real-life conditions?

British Journal of Psychiatry

Volumn 185, Issue AUG., 2004, Pages 93-94

  Verdoux, Hélène ^a,b   Bégaud, Bernard ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CENTRE HOSPITALIER CHARLES PERRENS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; OLANZAPINE; PSYCHOTROPIC AGENT; RISPERIDONE;

CLINICAL TRIAL; DRUG EFFICACY; ECONOMIC ASPECT; EDITORIAL; HUMAN; MEDICAL ETHICS; MENTAL DISEASE; PRACTICE GUIDELINE; PRESCRIPTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 4043050069     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.185.2.93     Document Type: Editorial

References (15)

1. Barbui, C., Danese, A., Guaiana, G., et al (2002) Prescribing second-generation antipsychotics and the evolving standard of care in Italy. Pharmacopsychiatry, 35, 239-243.
2. Bégaud, B. (2000) Dictionary of Pharmacoepidemiology. Chichester: John Wiley & Sons.
3. DeStefano, F. & Thompson, W. (2002) MMR vaccination and autism: is there a link? Expert Opinion on Drug Safety, 1, 115-120.
4. Donoghue, J. & Hylan, T. R. (2001) Antidepressant use in clinical practice: efficacy v. effectiveness. British Journal of Psychiatry, 179 (suppl. 42), S9-S17.
5. Koro, C. E, Fedder, D. O., L'Italien, G. J., et al (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ, 325, 243.
6. Lagnaoui, R., Begaud, B., Moore, N., et al (2002) Benzodiazepine use and risk of dementia: a nested case-control study. Journal of Clinical Epidemiology, 55, 314-318.
7. Madsen, K. M., Hviid, A., Vestergaard, M., et al (2002) A population-based study of measles, mumps, and rubella vaccination and autism. New England Journal of Medicine, 347, 1477-1482.
8. Martin, K., Bégaud, B., Latry, P., et al (2004a) Differences between clinical trials and post-marketing use. British Journal of Clinical Pharmacology, 57, 86-92.
9. Martin, K., Bégaud, B., Verdoux, H., et al (2004b) Patterns of risperidone prescription: a utilization study in Southwest France. Acta Psychiatrica Scandinavica, 109, 202-206.
10. Moynihan, R., Heath, I., Henry, D., et al (2002) Selling sickness: the pharmaceutical industry and disease mongering. BMJ, 324, 886-891.
11. Rey, J. M. &; Sawyer, M. G. (2002) Are psychostimulant drugs being used appropriately to treat child and adolescent disorders? British Journal of Psychiatry, 182, 284-286.
12. Sorensen, H. J., Mortensen, E. L., Reinisch, J. M., et al (2003) Do hypertension and diuretic treatment in pregnancy increase the risk of schizophrenia in offspring? American Journal of Psychiatry, 160, 464-468.
13. Verdoux, H. (2002) Long-term psychiatric and behavioural consequences of prenatal exposure to psychoactive drugs (in French). Thérapie, 57, 181-185.
14. Verdoux, H. & Cougnard, A. (2003) The early detection and treatment controversy in schizophrenia research. Current Opinion in Psychiatry, 16, 175-179.
15. Walker, A., Rosenberg, M. & Balaban-Gil, K. (1999) Neurodevelopmental and neurobehavioral sequelae of selected substances of abuse and psychiatric medications in utero. Child and Adolescent Psychiatric Clinics of North America, 4, 845-867.